Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

Inclusion Criteria: * Pathologically confirmed Non-Small Cell Lung Cancer at MSKCC * Clinical stage IIIB or IV. * Measurable disease as per RECIST * Greater than 6 months since receiving neo-adjuvant or adjuvant chemotherapy for Non-Small Cell Lung Cancer. * Age ≥ 18 years. * Karnofsky performance status of ≥ to 70. * Marrow and organ function as follows: * WBC ≥ to 4000/mm3 * Platelets ≥ to 160,000 * Bilirubin ≤ to 1.2mg/dL * Creatinine clearance ≥ to 40mL/min * AST and/or /ALT ≤ 37 Units/L (if one of these elevated, must be ≤ 2.5 ULN) * Systolic blood pressure ≤ to 150mmHg or diastolic blood pressure ≤ to 100 mmHg). * The subject is able to read and comprehend English text from a computer screen. * Women of childbearing potential and sexually active men enrolled in the study must agree to practice effective contraception. Exclusion Criteria: * Squamous cell carcinoma. * Prior treatment with paclitaxel, pemetrexed or bevacizumab for NSCLC. * Prior systemic anticancer therapy for advanced NSCLC. * Symptomatic brain metastases with evidence of hemorrhage. * Radiation therapy to greater than 25% of the bone marrow within 30 days of starting treatment. * Peripheral neuropathy greater than grade 1. * Malignancies within the past 5 years other than non-melanoma skin cancer. * Patients with other serious medical illnesses including, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements. * History of hemoptysis. * History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess. * History of myocardial infarction or stroke within 6 months prior to enrollment. * Pregnancy or lactation.